Neuroendocrine Tumors (NETs)
Incorporating the patient voice into our product development process aligns with Carevive’s mission in a genuine way.
In our latest patient engagement project, Carevive joined forces with the Neuroendocrine Cancer Awareness Network (NCAN), whose email and social media presence includes distribution to thousands of patients with cancer. Although Neuroendocrine Tumors (NETs) are considered rare, their prevalence has been steadily increasing due to better detection and awareness. NCANs mission is uniquely important in providing education and support to anyone impacted by NETs.
Connecting around the shared value of passion to support patients with NETs, Carevive Senior Content Developer April Guillen and NCAN’s Maryann Wahmann hosted a Zoominar for patients on Friday, November 6, 2020. April and Maryann shared their own oncology connections: April as an Oncology Certified Nurse spreading the word about remote symptom monitoring and Carevive’s ePRO solutions, and Maryann as a patient and advocate. Participants were invited to sign up as patient test users to help guide Carevive’s 2021 development, which will focus on patient engagement and patient values.
Carevive also distributed a survey to gather information to help us better understand the ways in which patients currently engage with technology for healthcare and symptom reporting. The survey is still open for patients to share their thoughts about their own oncology-care experience. Responses are anonymous. To participate, visit https://forms.gle/hdaRB3E3z8wDwjH47
Patients interested in joining to our pool of test users can register here: https://forms.gle/zWiQAFM1cfFVGwzV7
We look forward to sharing what patients are saying about reporting their symptoms remotely and how they feel about their interactions with their oncology team via Carevive’s technology.
Stay tuned in 2021 to see how insights from this project inform our value adds.